Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medical Advances Get More Chances When Safety Issues Arise

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.

You may also be interested in...



Safety Events For Accelerated Approval Drugs Highlighted As Expansion Looms

US drugs with accelerated approval are more likely to experience a postmarket safety event, JAMA study finds; data sharing could be a solution to filling information gaps.

Lower Level Of Innovation Could Undermine Expedited Approval Pathways

A Health Affairs study notes that the rate of serious post-marketing safety concerns has risen while PDUFA has pushed down drug review times, feeding into concerns about the increasing use of expedited approvals.

Drug Safety Forecast: Greater Understanding Could Signal Fewer Withdrawals

Efforts to foster innovation may have been the major theme for FDA in 2013, with new and expanded programs to expedite review of drugs for unmet medical needs dominating headlines, but senior agency officials also describe continued advances on the safety side of the regulatory equation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel